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The population pharmacokinetics of tafenoquine were studied in Australian soldiers taking tafenoquine for
malarial prophylaxis. The subjects (476 males and 14 females) received a loading dose of 200 mg tafenoquine
base daily for 3 days, followed by a weekly dose of 200 mg tafenoquine for 6 months. Blood samples were
collected from each subject after the last loading dose and then at weeks 4, 8, and 16. Plasma tafenoquine
concentrations were determined by liquid chromatography-tandem mass spectrometry. Population modeling
was performed with NONMEM, using a one-compartment model. Typical values of the first-order absorption
rate constant (Ka), clearance (CL/F), and volume of distribution (V/F) were 0.243 h
1, 0.056 liters/h/kg, and
23.7 liters/kg, respectively. The intersubject variability (coefficient of variation) in CL/F and V/F was 18% and
22%, respectively. The interoccasion variability in CL/F was 18%, and the mean elimination half-life was 12.7
days. A positive linear association between weight and both CL/F and V/F was found, but this had insufficient
impact to warrant dosage adjustments. Model robustness was assessed by a nonparametric bootstrap (200
samples). A degenerate visual predictive check indicated that the raw data mirrored the postdose concentra-
tion-time profiles simulated (n  1,000) from the final model. Individual pharmacokinetic estimates for
tafenoquine did not predict the prophylactic outcome with the drug for four subjects who relapsed with
Plasmodium vivax malaria, as they had similar pharmacokinetics to those who were free of malaria infection.
No obvious pattern existed between the plasma tafenoquine concentration and the pharmacokinetic parameter
values for subjects with and without drug-associated moderate or severe adverse events. This validated
population pharmacokinetic model satisfactorily describes the disposition and variability of tafenoquine used
for long-term malaria prophylaxis in a large cohort of soldiers on military deployment.
Tafenoquine, a synthetic analog of primaquine, is a new
8-aminoquinoline antimalarial drug being codeveloped by
GlaxoSmithKline Pharmaceuticals and the Walter Reed Army
Institute of Research (1). Clinical trials have shown tafeno-
quine to be an effective antimalarial agent that has been gen-
erally well tolerated, with transient gastrointestinal discomfort
being the most commonly reported adverse event (8, 10, 11, 13,
15). To date, it has been evaluated in more than 2,000 subjects
in six phase II clinical studies. Since tafenoquine acts on all
malaria stages, it has potential in the chemoprophylaxis of
malaria, in radical cure/relapse prevention of Plasmodium
vivax infections, and as a transmission-blocking agent (game-
tocytocidal activity).
The pharmacokinetics of tafenoquine in humans have been
derived from studies after oral administration, as no parenteral
formulation exists. Tafenoquine is slowly absorbed following
oral administration, with maximum plasma concentrations ob-
served at about 12-h postdose in fasted subjects (1). Plasma
tafenoquine concentration-time data have been described by a
one-compartment model with first-order absorption and elim-
ination (1, 2). The elimination half-life of tafenoquine is about
2 weeks. It is extensively distributed to tissues, with a large
volume of distribution and a low clearance, but data on the
metabolism of tafenoquine in humans are limited. Although
animal studies have shown that absorbed tafenoquine secreted
via the bile is found predominantly in the form of metabolites,
which accounted for the majority of the drug-related material
eliminated in the urine and feces, unchanged tafenoquine was
the only drug-related component detected in human plasma by
high-performance liquid chromatography–mass spectrometry
(HPLC-MS) and HPLC with fluorescence detection (Glaxo-
SmithKline Pharmaceuticals, unpublished data).
Tafenoquine is highly effective in preventing malaria infec-
tions following a weekly dose of either 200 mg or 400 mg for 13
weeks (13) or 400 mg monthly for 6 months (15). In developing
the dosage regimen for malaria prophylaxis, a phase III study
was conducted to assess the safety, tolerability, and effective-
ness of tafenoquine in Australian soldiers deployed for 6
months on peacekeeping duties to an area where malaria is
endemic. The full clinical results of that study will be published
elsewhere. The soldiers were on a weekly regimen of 200 mg of
tafenoquine, and blood samples were collected on four occa-
sions for drug analysis. No malaria infections occurred during
the prophylactic phase, but four soldiers were diagnosed with
P. vivax infection after returning to Australia.
The primary aim of the present study was to use these data
to develop a population pharmacokinetic model for tafeno-
quine and to estimate the disposition of this drug in the target
population of soldiers on military deployment. Secondary aims
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were to determine whether individual pharmacokinetic esti-
mates for tafenoquine would predict prophylactic outcomes
and to investigate if there was any relationship between taf-
enoquine concentrations and drug-associated adverse events.
MATERIALS AND METHODS
Study design and subjects. The clinical trial was designed as a prospective,
randomized, double-blind comparative study of the safety, tolerability, and ef-
fectiveness of tafenoquine and mefloquine in Australian soldiers on weekly
malaria prophylaxis. The subjects were deployed on peacekeeping duties to East
Timor for 6 months. They all were judged to be healthy by a complete medical
history, physical examination, and normal hematological and biochemical values.
They had to be glucose-6-phosphate dehydrogenase normal and willing and able
to give written informed consent and comply with the study protocol. Females
were excluded if they were pregnant, lactating, or unwilling/unable to comply
with recognized contraceptive methods. The study protocol received prior writ-
ten approval by the Australian Defence Human Research Ethics Committee and
the U.S. Army Human Subject Research Review Board.
Tafenoquine dosing regimen. Following a loading dose regimen of 200 mg
tafenoquine base daily for three consecutive days, the subjects then received an
oral weekly maintenance dose of 200 mg tafenoquine over approximately 6
months. An opaque Swedish Orange size 1 hard gelatin capsule (Capsugel)
containing tafenoquine at 200 mg (pure free base) was used as the dosage form.
Subjects were directed to take their tafenoquine with food (breakfast or dinner)
at the same time each week. Dosage administration was observed and recorded
for each subject.
Pharmacokinetic sampling. The sampling design was guided by the results
from a previous smaller study of Thai soldiers (2) and also by logistical issues of
the field operations. Blood samples were collected at prerandomized times after
the last loading dose and then at prerandomized times at weeks 4, 8, and 16.
Samples were collected on predetermined days after dosing on each of the
assessment weeks. The predetermined days included day 1 (early postdose;
absorption phase), days 3 and 5 (72 to 120 h postdose), and day 7 (predose;
trough phase). For example, on week 4, one group of soldiers (about 125 sub-
jects) was bled on day 1, one group was bled on day 3, one group was bled on day
5, and one group was bled on day 7. Thereafter, the groups of soldiers were bled
in a cyclical fashion such that at the end of the study each group had been bled
on at least one occasion on days 1, 3, 5, and 7. However, the sample for day 2 of
the study (1 to 12 h; post-final loading dose) was collected from the study
subjects.
Blood (7 ml) was drawn by venipuncture into EDTA tubes and transported on
ice bricks to the field laboratory within 3 h of collection. Whole-blood samples
were centrifuged at 1,200  g for 15 min (Sigma, Quantum, Australia), and
plasmas were separated and stored in liquid nitrogen (4 weeks) and then air
freighted on dry ice to Quintiles Limited (Edinburgh, United Kingdom) for
storage at 70°C until analysis. Tafenoquine was stable under these handling
and storage conditions.
Measurement of tafenoquine. Plasma tafenoquine concentrations were deter-
mined using a validated HPLC method with a triple-quadrupole mass spectrom-
eter. Briefly, plasma (0.05 ml) was spiked with [2H415N]tafenoquine as a stable-
isotope-labeled internal standard, and the protein was precipitated with
methanol, followed by centrifugation and then injection of 4 l of the superna-
tant fluid onto a reversed-phase HPLC column (4-m-diameter particles; Gen-
esis C18 column; 30 mm  2.1-mm internal diameter) held at 40°C. The mobile
phase was methanol-1 mM ammonium acetate buffer, pH 2.5 (70:30 [vol/vol]),
pumped at 1 ml/min and split approximately 1 to 4 into the TurboIonSpray
interface of a PE-Sciex API 3000 LC/MS/MS system (Applied Biosystems) op-
erated in positive-ion multiple-reaction monitoring mode. A chromatographic
cycle time of 1.3 min was used, with the peaks being eluted at 0.4 min. The
multiple-reaction monitoring transitions monitored were 464 to 379 m/z for
tafenoquine and 469 to 379 m/z for stable-isotope-labeled tafenoquine. Linear
responses in analyte/internal standard peak area ratios were observed for taf-
enoquine concentrations ranging from 5 to 500 ng/ml, using a weighted (1/C2)
linear regression. Results of a three-run validation gave an intra-assay impreci-
sion (coefficient of variation [CV%]) of 5.8% and an interassay imprecision of
7.3%, with an inaccuracy of 1.5 to 4.4%. The lower limit of quantification of the
method was 5 ng/ml.
Population pharmacokinetic modeling. The population pharmacokinetics of
tafenoquine were determined in double precision by using NONMEM (version
5, level 1.1; Globomax LLC, Hanover, MD) in conjunction with a G77 compiler.
A one-compartment model with first-order absorption and elimination was fitted
to the data, using first-order conditional estimation with interaction. An initial
analysis was conducted by permitting NONMEM to estimate the base model
parameters (i.e., no covariates). The influence of mean-centered continuous
variables, i.e., age, current weight, and estimated creatinine clearance (CLCR [by
the Cockcroft-Gault method]), and the categorical variables, i.e., sex or evidence
of phospholipidosis, was assessed by adding these to the base model in turn
and noting the change in the objective function value (OFV). The inclusion
of a covariate improved the fit of the data to the model if there was a decrease
in the OFV. The difference between a pair of OFV values when a covariate
was included (full model) and then excluded (reduced model) was tested for
significance (  0.01), using the chi-square statistic with 1 degree of freedom
(	21,0.01  6.6).
The interindividual variability (IIV) was modeled, assuming a log-normal
distribution, as follows:
CL/Fij CL/F  e
i,CL/F  Kj,CL/F
V/Fij V/F  e
i,V/F  Kj,V/F
Kaij Ka  e

i,Ka  Kj,Ka
where CL/Fjj, V/Fij, and Kaij represent the true but unknown values of the
parameters for the ith subject on the jth occasion about the typical respective
population values CL/F, V/F, and Ka. The parameters i,CL/F, i,V/F, and i,Ka are
random variables distributed with means of 0 and respective variances of 2CL/F,
2V/F, and 
2
Ka. K (kappa) is a random variable representing the variability of a
given pharmacokinetic parameter value on different occasions, with an occasion
being defined a priori as a dose or sequential doses followed by at least one
observation (in this study, there were typically four occasions). The interoccasion
variability (IOV) was assumed to be sampled from a normal distribution having
a mean of 0 and a variance of 2. In modeling the IOV, it was assumed that the
variances of each parameter were sampled from the same distribution. The
residual unexplained variability (RUV) among observed plasma tafenoquine
concentrations and those predicted by the final population model were estimated
by a combined proportional plus additive error model, as follows: Cij  Cpred,ij(1
 ε1,ij)  ε2,ij, where Cij is the ith observed concentration in the jth subject,
Cpred,ij is the plasma tafenoquine concentration predicted by the pharmacoki-
netic model, and ε1,ij and ε2,ij are randomly distributed variables having mean
values of 0 and variances of 12 and 22, respectively.
Model assessment. The final model was assessed by an inspection of standard
diagnostic plots of observed concentration versus population model predicted
concentration and separate plots of weighted residual versus model-predicted
concentration, elapsed time, subject identification, and screened covariates (3).
A degenerate visual predictive check was performed by simulating from the final
model 1,000 concentrations at each of 44 sampling times of up to 200 h postdose,
at week 1 (after the third loading dose), and then at weeks 4, 8, and 16 during
maintenance dosing. The 50th percentile concentration (as an estimator of the
population-predicted concentration) and the 5th and 95th percentile concentra-
tions were processed by ActivePerl (v.5.8.4; ActiveState) and then plotted against
elapsed time for each of the above four sampling windows. Observed tafeno-
quine concentrations were superimposed on the plots. Model robustness was
assessed by a nonparametric bootstrap, with replacement, of 200 NONMEM
runs of the final model, comparing the bootstrapped median parameter values
and the percentile bootstrap 90% confidence intervals (4, 5) with the respective
values estimated in the final model.
Adverse events, severity rating, and association with drug. As part of the
clinical phase III trial, adverse events were elicited by an investigator asking the
subject a nonleading question, such as “Do you feel differently in any way since
starting the new treatment?” A physician assessed the level of relationship of any
adverse event on the basis of the subject’s response and any temporal association
and/or known adverse responses to the drug. The physician graded the severity
of adverse events as follows: mild, not affecting daily activities; moderate, causing
some interference with daily activities; severe, daily duties could not be com-
pleted. Attribution or relationship to tafenoquine was judged by the physician to
be not related, unlikely to be related, suspected (reasonable probability) to be
related, or probably related.
RESULTS
Population characteristics. The study population consisted
of 476 males and 14 females, with a mean ( standard devia-
tion [SD]) age of 25.4  5.3 years (range, 18 to 47 years) and
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a mean ( SD) weight of 80.9  11.9 kg (range, 50 to 135 kg).
All but eight were of Caucasian background. Of the 490 sub-
jects, 2 subjects provided one blood sample, 3 subjects pro-
vided two blood samples, 23 subjects provided three blood
samples, and the remaining 462 subjects provided four blood
samples, giving a total of 1,925 plasma concentration-time
points available for the pharmacokinetic analyses.
Population pharmacokinetic modeling. Summary results of
the population model-building process are shown in Table 1.
The data did not support the inclusion of an absorption lag
time in any model. Neither age nor CLCR on CL/F significantly
improved the fit, nor did sex or phospholipidosis as indicator
variables. Both age and sex effects on V/F produced small but
significant decreases in the OFV, of 9 and 12, respectively. Use
of an allometric size model scaled to 70 kg for CL/F (power,
0.75) and V/F (power, 1.0) was not supported (OFV  37).
Inclusion of centered linear weight on both CL/F and V/F
significantly decreased the OFV, from 22,177 to 22,138. This
model predicted that a 1-kg change in weight from the popu-
lation average value of 80.9 kg would give a commensurate
change of 0.0167 liters/h (0.38%) in CL/F and a change of 9.7
liters (0.51%) in V/F. The linear, positive influence of weight
on both CL/F and V/F is shown in Fig. 1a and b, respectively.
Modeling the covariance between 2CL/F and 
2
V/F reduced
the OFV from 22,265 to 22,248 compared with the correspond-
ing model when 2CL/F and 
2
V/F were assumed to be inde-
pendent. Inclusion of the IOV for CL/F reduced the OFV
further, to 22,177. However, while the addition of IOV to V/F
further reduced the OFV, the value for 2V/F was suspiciously
low and the correlation coefficient (r) calculated from the di-
agonal and off-diagonal elements of the variance matrix [r 
2CL/F,V/F/(
2
CL/F  
2
CL/F)
0.5] was 1, indicating an inappro-
priate variance model. The RUV was best modeled by using a
combined proportional and additive model, as seen by an in-
crease in the OFV and by numerical difficulties when the
additive and proportional models were used separately.
Parameter values for the final population model and the
bootstrap validation are shown in Table 2. The estimated time
(Tmax) for peak concentration to occur after a dose was 21.4 
8.57 h, calculated from each subject’s conditional estimates of
Ka and Ke by the standard formula Tmax  ln(Ka/Ke)/(Ka  Ke)
for a one-compartment extravascular model. The observed
mean ( SD) peak tafenoquine concentration measured in
samples drawn within 5% of the time of the estimated mean
population Tmax (21.4 h) for 42 subjects at weeks 4, 8, and 16
was 321  63 ng/ml. The observed mean ( SD) trough taf-
enoquine concentration drawn within 5% of the target 168-h-
postdose sampling time for 162 subjects at weeks 4, 8, and 16
was 221  57 ng/ml. The typical population CL/F and V/F
FIG. 1. Relationship of body weight (WT) to individual estimates
of (a) CL/F and (b) V/F for tafenoquine.
TABLE 1. Development of structural model for pharmacokinetics of tafenoquine
Model Parameterizationd OFVa
1 CL/F  1; V/F  2; Ka  3
2 CL/F  1  (1  4  age/25.4); V/F  2; Ka  3 2
3 CL/F  1; V/F  2  (1  4  age/25.4); Ka  3 9
b
4 CL/F  1  (1  4  CLCR/121); V/F  2; Ka  3 4
5 CL/F  1  PHOS  4  (1  PHOS); V/F  2; Ka  3 0
6 CL/F  1; V/F  2  PHOS  4  (1  PHOS); Ka  3 1
b
7 CL/F  1  sex  4  (1  sex); V/F  2; Ka  3 3
b
8 CL/F  1; V/F  2  sex  4  (1  sex); Ka  3 12
9c CL/F  1  (1  4  WT/80.9); V/F  2  (1  5  WT/80.9); Ka  3 39
10 CL/F  1  (WT/70)
0.75; V/F  2  (WT/70)
1.0; Ka  3 37
b
a OFV, change in OFV from that of model 1 (OFV  22,177).
b Rounding errors occurred during fitting.
c Final model.
d WT/80.9, body weight (kg) centered on average weight (80.9 kg); age/25.4, age (years) centered on average age (25.4 years); CLCR/121, CLCR (ml/min) centered
on average CLCR (121 ml/min); PHOS, phospholipidosis (tested in 77 subjects; 1  phospholipidosis present, 0  phospholipidosis not present); sex, male  0 and
female  1.
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values for all subjects, with a mean weight of 80.9 kg, were 4.37
liters/h and 1,901 liters, respectively. The typical value of Ka
over all subjects was 0.243 h1. The IIV about CL/F, V/F, and
Ka was 18%, 22%, and 76%, respectively. The IOV for CL/F
was 18%. Mean values per kg for CL/F and V/F calculated
from conditional estimates for each subject were 0.056  0.013
liters/h/kg and 23.7  4.5 liters/kg, respectively. The elimina-
tion half-life (t1/2), derived from the expression t1/2 
(0.693  V/F)/(CL/F) with individual estimates of CL/F and
V/F, was 12.7  3.0 days.
Routine diagnostic weighted residuals versus population
model-predicted values (data not shown) were symmetrically
distributed and were mostly within about 3 units of the null
ordinate, indicating a good fit of the model to the data. Plots of
weighted residuals versus both subject identification and time
(data not shown) were distributed symmetrically in a band with
no obvious trend and were mostly within approximately 3 units
of the null ordinate, indicating that no time-related factor
affected the data and that no subject’s data contributed to any
marked deviation from the model. The bootstrapped median
parameter values very closely agreed with the respective values
from the final population model (Table 2). The degenerate
visual predictive check showed the observed data to be sym-
metrically distributed about the 50th percentile profile, with
approximately 10% of the data distributed outside the 5th- to
95th-percentile boundaries (Fig. 2a, b, c, and d).
Individual pharmacokinetics of tafenoquine in subjects with
malaria and with drug-associated adverse events. The four
subjects who had a relapse after returning to Australia had a
mean ( SD) CL/F of 0.060  0.014 liters/h/kg, a V/F of 23.2 
8.0 liters/kg, and a t1/2 of 11.1  2.3 days, calculated from
conditional parameter estimates for each individual.
One or more adverse events with a suspected/probable re-
lationship to tafenoquine were reported by 73 subjects. These
were ranked as mild in 67 subjects (91.8%), moderate in 5
subjects (6.8%), and severe in 1 subject (1.4%) and encom-
passed the following: nausea, abdominal pain, flatulence, vom-
iting, vertigo, agitation, amnesia, headache, eye abnormality,
reflux, dreaming abnormality, insomnia, somnolence, diarrhea,
hyperesthesia, tremor, paranoia, headache, anorexia, depres-
sion, coordination abnormality, appetite increase, and thirst.
Tafenoquine was not withdrawn in any of the 67 mild cases, but
it was withdrawn for three subjects who reported either mod-
erate hyperesthesia, abdominal pain, or depression. Assess-
ment for phospholipidosis was carried out in a subgroup of 77
subjects because tafenoquine has cationic amphiphilic charac-
teristics and, therefore, the potential to cause phospholipid
accumulation. Table 3 shows adverse events reported in the
five moderate cases and one severe case where tafenoquine
was suspected to cause the discomfort, together with individual
estimates of the pharmacokinetic responses for these subjects.
All moderate adverse events were experienced 1 to 24 days
after the initiation of tafenoquine, while the single subject with
FIG. 2. Degenerate visual predictive check of the final population
model for tafenoquine. Plots are shown for plasma tafenoquine con-
centration versus postdose time in sampling windows of (a) week 1
(post-loading dose), (b) week 4, (c) week 8, and (d) week 16. The
population-predicted profile (50th percentile) is shown by the solid
line, and the 90% prediction intervals estimated from 1,000 simulated
concentrations over 200 h (postdose) are encompassed by the broken
lines in each plot.
TABLE 2. Comparison of parameter estimates for the population
model with the results of 200 bootstrapped runs
Parameter and model Final modelvalue
Bootstrap value
(n  200)
(median 90% CI)b
Structural modela
CL/F (1; liters/h) 3.02 3.01 (2.42–3.52)
V/F (2; liters) 1,110 1,110 (874–1,382)
Ka (3; h
1) 0.243 0.245 (0.212–0.280)
Weight centered on CL/Fc 0.448 0.447 (0.249–0.816)
Weight centered on V/Fd 0.713 0.713 (0.371–1.20)
Variance model
IIVCL/F (CV%) 18 18 (16–20)
IIVV/F (CV%) 22 22 (20–25)
IIVKa (CV%) 76 75 (64–85)
IOVCL/F (CV%) 18 18 (16–20)
RUV (CV%) 5.9 5.9 (4.7–7.4)
RUV (ng/ml) 22.9 23.1 (18.7–26.3)
a CL/F  1  (1  4  WT/80.9); V/F  2  (1  5  WT/80.9); Ka  3.
b Percentile bootstrap 90% confidence interval (5th to 95th percentiles).
c Linear coefficient (4) for weight centered on CL/F.
d Linear coefficient (5) for weight centered on V/F.
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severe effects reported diarrhea and abdominal pain 2 days
after commencing tafenoquine treatment.
DISCUSSION
This study of the population pharmacokinetics of tafeno-
quine in 490 Australian soldiers is the largest undertaken by far
with this promising new oral antimalarial agent. Previously, a
two-stage dose-ranging pharmacokinetic study was performed
with 48 healthy adult males (Caucasian [n  20], African-
American [n  12], and Hispanic [n  16]) (1), while a sub-
sequent population pharmacokinetic study was reported for
104 Thai soldiers on a monthly prophylactic regimen of taf-
enoquine (2). The present findings confirm the knowledge of
tafenoquine disposition in humans and considerably extend the
pharmacokinetic data to a large population of healthy, Cauca-
sian military personnel deployed in field operations.
The apparent V/F was similar to that reported by Edstein et
al. (2), but the systemic CL/F was greater (4.37 liters/h versus
3.20 liters/h). The derived typical elimination t1/2 of 12.7 days
was slightly shorter than the 14 to 16 days reported previously,
which may partly reflect the fact that the last samples were
drawn at only up to 1 week postdose and therefore the pre-
sumed “terminal” phase may have included some components
of a distribution phase, but not substantial enough to be sup-
ported by a two-compartment model. The mean values for
CL/F and V/F obtained by Brueckner et al. (1) for fasted
subjects of similar average weight to that from this study were
5.7 liters/h and 2,558 liters, respectively, which are 30% to 35%
higher than the present typical values. However, in the current
study, the subjects took tafenoquine with food, which report-
edly can increase the bioavailability (F) by up to one-third
(R. P. Brueckner, personal communication), which brings the
respective CL/F and V/F values into closer agreement when
corrected for F. While the extent of tafenoquine absorption
may be greater, food could also slow the rate of drug absorp-
tion, as evidenced by the typical Ka of 0.243 h
1, compared
with 0.391 h1 and 0.694 h1 reported by Brueckner et al. (1)
and Edstein et al. (2), respectively. As a result, the average
Tmax of 21.4 h was greater than the 8.6 h to 13.8 h reported
previously (1, 2), which as well as the influence of food, may
reflect continuous absorption along the intestinal tract, per-
haps due in part to microprecipitation and redissolution of
tafenoquine, which is only slightly water soluble (1). Unpub-
lished data on file (GlaxoSmithKline) for healthy volunteers
showed mean (CV%) Tmax values of 18.6 h (84%) and 26.3 h
(126%) under fasted conditions and when administered with a
standard high-fat meal, respectively, indicating that the Tmax
and its variability were increased by food. Nonetheless, it
should be remembered that Tmax is a model-dependent param-
eter in that the true value is likely to be overestimated when a
one-compartment model is used compared with that for a
two-compartment model. In agreement with previous reports
(1, 2), there was marked IIV in the Tmax, reflecting the con-
siderable variability in both Ka and Ke, with the latter being
estimated from conditional estimates of V/F and CL/F for each
subject.
The variability in CL/F and V/F was not excessive, at 18% to
22%, most likely reflecting the uniformity of the military sub-
jects. The variance model supported estimation of the IOV in
CL/F but not that in V/F or Ka. While Edstein et al. (2) used a
proportional (exponential) model for RUV, presently a com-
bined additive-proportional RUV model was supported, which
is the preferred model wherever possible, especially where the
range of concentration data is as wide as in this study. There
was a positive linear association between weight and both CL/F
and V/F, but attempts to model these parameters using an
allometric size model scaled to 70 kg were not supported by the
data, most likely because of the reasonably narrow range of
body weights. Although heavier subjects tended to have a
slightly greater CL/F and V/F, this would not have any major
implications for changes in the way that tafenoquine would be
prescribed, at least on the basis of the pharmacokinetic data
alone. Using the present steady-state plasma tafenoquine con-
centrations as the appropriate clinical target, a 20-kg change in
weight would require changes in the loading dose and main-
tenance dose of only about 10% and 7.5%, respectively. Un-
published data (GlaxoSmithKline) indicated that a consider-
able fraction of a tafenoquine dose may be excreted
unchanged, while the clinical data from the trial of which the
present study was a part showed that mean serum creatinine
concentrations increased 12.1 mmol/liter from baseline until
the end of the prophylaxis. However, estimated creatinine
clearance explained an insignificant amount of the variability
TABLE 3. Tafenoquine pharmacokinetic data for six subjects reporting at least one adverse effect classified as
severe (n  1) or moderate (n  5)
Adverse event
Treatment
duration
(days)a
Cumulative
dose (mg)b
Dosing
stopped
Clast
(ng/ml)c
CL/F
(liters/h/kg)
V/F
(liters/kg)
t1⁄2
(days)
Severe event
Diarrhea and/or abdominal pain 2 400 No * 0.059 24.4 12.0
Moderate events
Insomnia 1 200 No * 0.059 23.2 11.3
Hyperesthesia 12 800 Yes 283 0.046 20.7 13.1
Abdominal pain 20 1,000 Yes 253 0.053 27.8 15.1
Depression 24 1,000 Yes 275 0.061 25.1 12.0
Vomiting and/or nausea 3 600 No 315 0.077 26.1 9.8
a Number of days from starting dosing until adverse event reported.
b Total amount of drug taken before adverse event reported.
c Last plasma tafenoquine concentration before adverse event reported. *, adverse event was reported before first plasma sample was drawn.
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about CL/F. Age explained a small yet significant amount of
the variability in both V/F and CL/F but was positively corre-
lated with weight and thus was not considered further.
In assessing performance, model robustness was evaluated
via a nonparametric bootstrap, which indicated that randomly
selected combinations of data gave very similar results to those
obtained with the original data set. In addition, a degenerate
visual predictive check showed that the raw data obtained after
the third split loading dose and at week 4, 8, and 16 during
maintenance dosing mirrored the corresponding profiles ob-
tained from simulations using point estimates of the final
model parameter values. This convenient approach has been
shown elsewhere (16) to give a good approximation of the full
posterior predictive check, in which the simulations are per-
formed using posterior distributions of the parameter values
(6), which are difficult to calculate from the NONMEM out-
put. The predictive check showed, firstly, that the structural
model was satisfactory by the symmetrical distribution of the
raw data about the 50th percentile profile and, secondly, that
the variance model was appropriate, with about 10% of the raw
data lying outside the 5th and 95th percentiles.
The prophylactic efficacy of tafenoquine is determined by its
ability to prevent parasitemia from developing, which is asso-
ciated with the susceptibility of malaria parasites to tafeno-
quine concentrations achieved in the target population. Taf-
enoquine has both causal prophylactic activity against the
hepatic stages of the parasite and suppressive activity, which
eradicates the erythrocytic stages of the parasite (1). In the
present study, no subject developed parasitemia during the 6
months of prophylaxis, but four had a relapse of P. vivax in-
fection after returning to Australia. In contrast, one subject in
a population of 104 Thai soldiers on 400 mg tafenoquine
monthly for 6 months developed vivax malaria during prophy-
laxis (15). At the time of diagnosis, the Thai soldier had a
plasma tafenoquine concentration of 40 ng/ml, which was 5-
fold lower than the mean steady-state trough tafenoquine con-
centration of 221 ng/ml presently recorded. Six Australian sol-
diers had tafenoquine concentrations of 100 ng/ml at either
week 4, 8, or 16. Of those, only one subject had consistently
lower tafenoquine concentrations (120 ng/ml) on the three
occasions sampled and therefore may have had a reduced
margin of suppressive protection against malaria infection.
The Thai soldier who developed parasitemia also had consis-
tently lower tafenoquine concentrations during the prophylac-
tic phase (15). Unlike the Thai soldier, the four Australian
soldiers who relapsed had comparable tafenoquine concentra-
tions to subjects who did not have a recurrence of malaria.
Although the number of subjects who relapsed was small, the
individual estimates of the pharmacokinetic responses for
these subjects did not provide a prediction or correlation with
tafenoquine’s prophylactic efficacy.
There was no apparent correlation between either the phar-
macokinetic parameter values predicted for individual subjects
or the last tafenoquine concentration measured in subjects
reporting moderate or severe adverse events. These findings
suggested that plasma tafenoquine concentrations are not the
primary predictor of tafenoquine tolerability. This lack of an
association between plasma drug concentrations and adverse
events has also been seen with another antimalarial agent,
mefloquine, which shares similar pharmacokinetic properties
with tafenoquine (12) in that both are lipophilic, are slowly
absorbed from the gastrointestinal tract, are extensively bound
to tissues, and have elimination t1/2 values of about 2 weeks (1,
2, 9, 14).
In conclusion, the pharmacokinetic properties of tafeno-
quine determined in this study support a weekly dosing regi-
men for prolonged periods. Although body weight influenced
CL/F and V/F, it was not considered to have sufficient impact
to warrant changing the maintenance or loading dose for any
individual from such a population. Nonetheless, dose changes
may be warranted for other patients who are markedly over-
weight or underweight compared with this homogenous group
of soldiers. Any dosing requirements for markedly overweight
subjects may need special consideration, as reviewed recently
(7). Tafenoquine was generally well tolerated. Individual phar-
macokinetic parameter estimates for subjects with malaria did
not predict prophylactic outcomes, and plasma concentrations
at steady state did not appear to be related to the occurrence
of adverse events. Since this population was a homogenous
group of healthy Australian soldiers of predominantly Cauca-
sian background, additional pharmacokinetic studies may be
required for other populations.
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